NDC 82009-160 – Ustekinumab-ttwe
Ustekinumab 45 mg/.5mL · Injection, Solution · Subcutaneous
Product NDC82009-160
Product details
- Brand name
- Ustekinumab-ttwe
- Generic name
- Ustekinumab-ttwe
- Labeler
- Quallent Pharmaceuticals Health LLC
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761373
- Marketed since
- April 15, 2025
- Listing expires
- December 31, 2027
- Pharmacologic class
- Interleukin-12 Antagonist; Interleukin-23 Antagonist
Active ingredients
- Ustekinumab 45 mg/.5mL
Uses, dosage, side effects and warnings for Ustekinumab-ttwe →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 82009-160-11 | 1 SYRINGE in 1 CARTON (82009-160-11) / .5 mL in 1 SYRINGE | Apr 15, 2025 |